AMAG Pharmaceuticals, Inc.

$AMAG - Nasdaq - Pharmaceuticals and Biotechnology
0 LAST
0 CHANGE $
0 CHANGE %
loader
ON 0
WATCHLISTS

COMMUNIQUÉ DETAILS

Up 0 0 Down
AMAG Pharmaceuticals Announces Presentation at Jefferies 2013 Global Healthcare Conference in London

WALTHAM, Mass., Nov. 15, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG), a specialty pharmaceutical company, announced today that Frank Thomas, AMAG's chief operating officer, will present at the Jefferies 2013 Global Healthcare Conference in London on Thursday, November 21, 2013 at 8:00 a.m. GMT. The session will include a company presentation followed by a question and answer session, in which the company's business, strategy and growth prospects will be discussed.

A live webcast of the presentation will be accessible through the Investors section of the company's website at www.amagpharma.com. Following the conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website for 90 days.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that markets Feraheme® (ferumoxytol) Injection and MuGard® Mucoadhesive Oral Wound Rinse in the United States. Along with driving organic growth of its products, AMAG intends to expand its portfolio with additional commercial-stage specialty products. The company is seeking complementary products that leverage the company's commercial footprint and focus on hematology and oncology centers and hospital infusion centers. For additional company information, please visit www.amagpharma.com.

AMAG Pharmaceuticals and Feraheme are registered trademarks of AMAG Pharmaceuticals, Inc.; MuGard is a registered trademark of Access Pharmaceuticals, Inc.

CONTACT: AMAG Pharmaceuticals, Inc. contact:
         Amy Sullivan, 617-498-3303

Source: AMAG Pharmaceuticals, Inc.
SHARE THIS: Twitter StockTwits LinkedIn Google Plus SHORT URL: http://bdvt.co/czue

SIGN IN TO BOARDVOTE

FORGOT PASSWORD?